MedPath

Effect of Photobiomodulation on Pain Control After Placement of Elastomeric Spacers.

Not Applicable
Active, not recruiting
Conditions
Inflammation
Interventions
Radiation: Photobiomodulation
Other: Simulation of Photobiomodulation
Registration Number
NCT05924204
Lead Sponsor
University of Nove de Julho
Brief Summary

Recent studies have shown that photobiomodulation (FBM) can modulate pain after the placement of elastomeric separators, however, to date, there is no ideal protocol for its application. Therefore, the objective of this study will be to evaluate the effect of photobiomodulation on pain control 24 hours after the placement of elastomeric separators using the visual analog scale (VAS). 25 patients between 13 and 30 years old with the need for the placement of orthodontic bands in the lower first molars bilaterally will be included, which establishes a sample of fifty molars.

Elastomeric separators will be placed on the mesial and distal surfaces of the right and left molars. Treatment will be randomized to the right molar and the opposite treatment will be applied to the left side. The study groups will be G1 (experimental) - elastomeric separators + FBM (diode laser, 808nm, 100mw power, with 2 J, 3 points per vestibular and 3 points per palatal, single session, 707J/cm2) and G2-(control)- elastomeric separators + FBM simulation. The patient and the evaluator will be blinded to the intervention performed. The primary outcome variable will be spontaneous pain assessed 24 hours after the placement of elastomeric separators measured with the VAS scale. Secondary outcome variables will be pain during mastication (measured with the VAS scale), count of the number of analgesics (paracetamol), local temperature (measured with a digital thermometer), and assess the impact of oral health on quality of life. of the participant, the OHIP-14 questionnaire will be applied. These outcomes will be evaluated at baseline, 24 with the presence of the participant, and 72 hours after the placement of elastomeric separators. If the data are normal, they will be submitted to the ANOVA - one-way test. Data will be presented as means ± SD and the p-value will be set to \< 0.05.

Detailed Description

This randomized, controlled, double-blind, split-mouth clinical trial meets the criteria for designing a clinical study under the conditions of the SPIRIT Statement. The study was approved by the Committee for Ethics in Research (CEP) of the Universidad Católica del Uruguay. The participants who will be recruited are patients who are undergoing orthodontic treatment at the Orthodontic Clinic of the Specialization Course in Orthopedics and Orthodontics at the Catholic University of Uruguay in the city of Montevideo, Uruguay; those who require the installation of bands on the lower first permanent molars.

Any change or change will be reported and clarified to the CEP and informed in publications. A copy of the signed informed consent will be sent to the participant by email (completed in the TCLE). The project will be registered at www.clinicaltrial.gov There is no conflict of interest about any product used in the work and about any author involved in the studio. The data will be published and there will be no restriction on the inclusion of data for publication. All data will be available for your consultation, and all patients will have access to their medical records at any time they wish.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
25
Inclusion Criteria
  • Patients will include:

    • With the need to place bilateral orthodontic bands on the lower first molars.
    • Age 13 to 30 years old.
    • Both sexes.
    • No comorbidities.
    • Never used orthodontic appliances.
    • Preserved surrounding spaces.
    • Healthy permanent dentition with good hygiene.
Exclusion Criteria
  • Patients will be excluded:

    • Who are taking drugs that affect bone metabolism and the inflammatory process (for example corticosteroids, bisphosphonates), who have used anti-inflammatory drugs or analgesics for less than 1 week since placing elastomeric separators.
    • Present general pathologies (craniofacial anomalies) and local ones (dental anomalies) that affect the result of the movement of the teeth,
    • Smokers, embarrassed, or breastfeeding women.
    • Allergic to paracetamol®
    • During the investigation, another different drug was used, which was made available by the investigators, and the patient was informed about this alteration.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
G1 TREATMENT GROUPPhotobiomodulationIn the Treatment group the FMB with 4 J of energy by point
G2 SHAM GROUPSimulation of PhotobiomodulationIn the Sham group, the the device will be turned off
Primary Outcome Measures
NameTimeMethod
pain control after placement of elastomeric spacers - 24 hours24 hours

Visual analog scale measuing 0 to 10 were "0" is no pain and "10" is the worst pain in life

pain control after placement of elastomeric spacers - 72 hours72 hours

Visual analog scale measuing 0 to 10 were "0" is no pain and "10" is the worst pain in life

pain control after placement of elastomeric spacers - baselinebaseline

Visual analogue scale

Secondary Outcome Measures
NameTimeMethod
The quality of life related to oral health baselinebaseline

will be evaluated using the OHIP-14 questionnaire

Number of analgesics taken baselinebaseline

The analgesic used will only be paracetamol. It will be used only if there is pain.

Number of analgesics taken 3 days3 days after procedure

The analgesic used will only be paracetamol. It will be used only if there is pain.

Local temperature 24 hours24 hours

evaluated using a digital thermometer

Local temperature baselinebaseline

evaluated using a digital thermometer

The quality of life related to oral health -72 hours72 hours

will be evaluated using the OHIP-14 questionnaire

Trial Locations

Locations (1)

Anna Carolina R.T. Horliana

🇧🇷

São Paulo, SP, Brazil

© Copyright 2025. All Rights Reserved by MedPath